Sickle cell disease is one of the most common inherited blood disorders worldwide, with a particularly heavy burden in ...

Cellarity has dosed the first subject in a Phase I study of oral medication, CLY-124, to treat sickle cell disease (SCD).

Participants in the World Sickle Cell Disease Awareness Day event included ImpactLife staff members as well as community ...

Emerging Sickle Cell Disease therapies in the different phases of clinical trials are- RL 101, ORY-300, GSK 4172239D, AG-946, BEAM-101, Nula-cel, RG 6107, Isoquercetin, Renizgamglogene ...

At Miami-Dade’s public hospital system Jackson Health, new advancements in genetic research recently helped doctors modify a ...

Cellarity Initiates Phase 1 Clinical Study of CLY-124, a First-in-Class Globin-Switching Oral Medicine for the Treatment of Sickle Cell Disease Provided by PR Newswire Jun 26, 2025, 4:30:00 AM ...

Dr Rossby Awadzi, a GP trainee and Sickle Cell Clinical Fellow at NHS England with a passion for red cell medicine, explains ...

Dr. Omar H. Llaguna, specialist in surgical oncology, programs a HistoSonics medical device for targeting a medium that ...

Sickle cell disease refers to a group of inherited blood disorders with symptoms like anaemia and blocked blood vessels. About 80% of the world's sickle cell disease cases occur in sub-Saharan Africa.